Opposite regulation of the rat and human cytosolic aspartate aminotransferase genes by fibrates

Biochemical Pharmacology

Volumn 67, Issue 2, 2004, Pages 213-225

  Tomkiewicz, Céline ^a   Muzeau, Françoise ^a   Edgar, Alan D ^b   Barouki, Robert ^a   Aggerbeck, Martine ^a  

^a INSERM   (France)

^b Laboratoires Fournier SA   (France)

Author keywords

Aspartate aminotransferase; Fenofibrate; Human promoter sequencing; Peroxisome proliferators; PPAR ; Transaminases

Indexed keywords

ASPARTATE AMINOTRANSFERASE; FENOFIBRATE; NUCLEAR PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; GENE CONTROL; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN VERSUS ANIMAL COMPARISON; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; RAT; REGULATOR GENE; WILD TYPE;

EID: 1642457239     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2003.07.018     Document Type: Article

References (41)

1. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., Fruchart J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 98:1998;2088-2093.
2. Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20:1999;649-688.
3. Staels B., van Tol A., Andreu T., Auwerx J. Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. Arterioscler Thromb. 12:1992;286-294.
4. Reddy J.K., Azarnoff D.L., Hignite C.E. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature. 283:1980;397-398.
5. Lee S.S., Pineau T., Drago J., Lee E.J., Owens J.W., Kroetz D.L., Fernandez-Salguero P.M., Westphal H., Gonzalez F.J. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15:1995;3012-3022.
6. DeLuca J.G., Doebber T.W., Kelly L.J., Kemp R.K., Molon-Noblot S., Sahoo S.P., Ventre J., Wu M.S., Peters J.M., Gonzalez F.J., Moller D.E. Evidence for peroxisome proliferator-activated receptor (PPAR)alpha-independent peroxisome proliferation: effects of PPARgamma/delta-specific agonists in PPARalpha-null mice. Mol. Pharmacol. 58:2000;470-476.
7. Pacot C., Petit M., Rollin M., Behechti N., Moisant M., Deslex P., Althoff J., Lhuguenot J.C., Latruffe N. Difference between guinea pig and rat in the liver peroxisomal response to equivalent plasmatic level of ciprofibrate. Arch. Biochem. Biophys. 327:1996;181-188.
8. Cooper AJL, Meister A. Metabolic significance of transamination. In: Christen P, Metzler DE, editors. Transaminases. New York: Wiley; 1985. p. 534-57.
9. Aggerbeck M., Garlatti M., Feilleux-Duché S., Veyssier C., Daheshia M., Hanoune J., Barouki R. Regulation of the cytosolic aspartate aminotransferase housekeeping gene promoter by glucocorticoids, cAMP and insulin. Biochemistry. 32:1993;9065-9072.
10. Barouki R., Pave-Preux M., Bousquet-Lemercier B., Pol S., Bouguet J., Hanoune J. Regulation of cytosolic aspartate aminotransferase mRNAs in the Fao rat hepatoma cell line by dexamethasone, insulin and cyclic AMP. Eur. J. Biochem. 186:1989;79-85.
11. Horio Y., Tanaka T., Taketoshi M., Uno T., Wada H. Rat cytosolic aspartate aminotransferase: regulation of its mRNA and contribution to gluconeogenesis. J. Biochem. (Tokyo). 103:1988;805-808.
12. Rej R. Aspartate aminotransferase activity and isoenzyme proportions in human liver tissues. Clin. Chem. 24:1978;1971-1979.
13. Edgar A.D., Tomkiewicz C., Costet P., Legendre C., Aggerbeck M., Bouguet J., Staels B., Guyomard C., Pineau T., Barouki R. Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor alpha-dependent pathway. Toxicol. Lett. 98:1998;13-23.
14. Deschatrette J. Dedifferentiated variants of a rat hepatoma: partial reversion induced by cell aggregation. Cell. 22:1980;501-511.
15. Knowles B.B., Howe C.C., Aden D.P. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science. 209:1980;497-499.
16. Pavé-Preux M., Aggerbeck M., Veyssier C., Bousquet-Lemercier B., Hanoune J., Barouki R. Hormonal discrimination among transcription start sites of aspartate aminotransferase. J. Biol. Chem. 265:1990;4444-4448.
17. Bousquet-Lemercier B., Pol S., Pave-Preux M., Hanoune J., Barouki R. Properties of human liver cytosolic aspartate aminotransferase mRNAs generated by alternative polyadenylation site selection. Biochemistry. 29:1990;5293-5299.
18. Garlatti M., Tchesnokov V., Daheshia M., Feilleux-Duche S., Hanoune J., Aggerbeck M., Barouki R. CCAAT/enhancer-binding protein-related proteins bind to the unusual promoter of the aspartate aminotransferase housekeeping gene. J. Biol. Chem. 268:1993;6567-6574.
19. Pavé-Preux M., Ferry N., Bouguet J., Hanoune J., Barouki R. Nucleotide sequence and glucocorticoid regulation of the mRNAs for the isoenzymes of rat aspartate aminotransferase. J. Biol. Chem. 263:1988;17459-17466.
20. Massaad C., Lombes M., Aggerbeck M., Rafestin-Oblin M.E., Barouki R. Cell-specific, promoter-dependent mineralocorticoid agonist activity of spironolactone. Mol. Pharmacol. 51:1997;285-292.
21. Beurton F., Bandyopadhyay U., Dieumegard B., Barouki R., Aggerbeck M. Delineation of the insulin-responsive sequence in the rat cytosolic aspartate aminotransferase gene: binding sites for hepatocyte nuclear factor-3 and nuclear factor I. Biochem. J. 343:1999;687-695.
22. Morel Y., Barouki R. Down-regulation of cytochrome P450 1A1 gene promoter by oxidative stress. Critical contribution of nuclear factor 1. J. Biol. Chem. 273:1998;26969-26976.
23. Hertz R., Seckbach M., Zakin M.M., Bar-Tana J. Transcriptional suppression of the transferrin gene by hypolipidemic peroxisome proliferators. J. Biol. Chem. 271:1996;218-224.
24. Jiang G., Sladek F.M. The DNA binding domain of hepatocyte nuclear factor 4 mediates cooperative, specific binding to DNA and heterodimerization with the retinoid X receptor alpha. J. Biol. Chem. 272:1997;1218-1225.
25. Garlatti M., Daheshia M., Slater E., Bouguet J., Hanoune J., Beato M., Barouki R. A functional glucocorticoid-responsive unit composed of two overlapping inactive receptor-binding sites: evidence for formation of a receptor tetramer. Mol. Cell. Biol. 14:1994;8007-8017.
26. Feilleux-Duche S., Garlatti M., Aggerbeck M., Bouguet J., Hanoune J., Barouki R. Phorbol esters inhibit the glucocorticoid-mediated stimulation of cytosolic aspartate aminotransferase gene transcription. Biochem. J. 297:1994;497-502.
27. Holden P.R., Tugwood J.D. Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences. J. Mol. Endocrinol. 22:1999;1-8.
28. Marrapodi M., Chiang J.Y. Peroxisome proliferator-activated receptor alpha (PPARalpha) and agonist inhibit cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. J. Lipid Res. 41:2000;514-520.
29. Vu-Dac N., Chopin-Delannoy S., Gervois P., Bonnelye E., Martin G., Fruchart J.C., Laudet V., Staels B. The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J. Biol. Chem. 273:1998;25713-25720.
30. Sakai M., Matsushima-Hibiya Y., Nishizawa M., Nishi S. Suppression of rat glutathione transferase P expression by peroxisome proliferators: interaction between Jun and peroxisome proliferator-activated receptor alpha. Cancer Res. 55:1995;5370-5376.
31. Gervois P., Vu-Dac N., Kleemann R., Kockx M., Dubois G., Laine B., Kosykh V., Fruchart J.C., Kooistra T., Staels B. Negative regulation of human fibrinogen gene expression by PPAR(alpha) agonists via inhibition of C/EBPbeta. J. Biol. Chem. 20:2001;20.
32. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J.M., Gonzalez F.J., Fruchart J.C., Tedgui A., Haegeman G., Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J. Biol. Chem. 274:1999;32048-32054.
33. Pan D.A., Mater M.K., Thelen A.P., Peters J.M., Gonzalez F.J., Jump D.B. Evidence against the peroxisome proliferator-activated receptor alpha (PPARalpha) as the mediator for polyunsaturated fatty acid suppression of hepatic L-pyruvate kinase gene transcription. J. Lipid Res. 41:2000;742-751.
34. Tolon R.M., Castillo A.I., Aranda A. Activation of the prolactin gene by peroxisome proliferator-activated receptor-alpha appears to be DNA binding-independent. J. Biol. Chem. 273:1998;26652-26661.
35. Johnson T.E., Ledwith B.J. Peroxisome proliferators and fatty acids negatively regulate liver X receptor-mediated activity and sterol biosynthesis. J. Steroid Biochem. Mol. Biol. 77:2001;59-71.
36. Balfour J.A., McTavish D., Heel R.C. Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs. 40:1990;260-290.
37. Palmer C.N., Hsu M.H., Griffin K.J., Raucy J.L., Johnson E.F. Peroxisome proliferator activated receptor-alpha expression in human liver. Mol. Pharmacol. 53:1998;14-22.
38. Tugwood J.D., Aldridge T.C., Lambe K.G., Macdonald N., Woodyatt N.J. Peroxisome proliferator-activated receptors: structures and function. Ann. N.Y. Acad. Sci. 804:1996;252-265.
39. Hsu M.H., Savas U., Griffin K.J., Johnson E.F. Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor alpha in HepG2 cells. J. Biol. Chem. 276:2001;27950-27958.
40. Lawrence J.W., Li Y., Chen S., DeLuca J.G., Berger J.P., Umbenhauer D.R., Moller D.E., Zhou G. Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha. PPAR alpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expression. J. Biol. Chem. 276:2001;31521-31527.
41. Rodriguez C., Noe V., Cabrero A., Ciudad C.J., Laguna J.C. Differences in the formation of PPARalpha-RXR/acoPPRE complexes between responsive and nonresponsive species upon fibrate administration. Mol. Pharmacol. 58:2000;185-193.